NCT00005940 - Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 1999

Primary Completion Date

January 31, 2006

Conditions

Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions

RADIATION

iodine I 131 monoclonal antibody BC8

Given IV

DRUG

busulfan

Given PO

DRUG

cyclophosphamide

Given IV

PROCEDURE

allogeneic bone marrow transplantation

Undergo allogeneic PBSC or bone marrow transplant

PROCEDURE

allogeneic hematopoietic stem cell transplantation

Undergo allogeneic PBSC or bone marrow transplant

PROCEDURE

peripheral blood stem cell transplantation

Undergo allogeneic PBSC or bone marrow transplant

DRUG

cyclosporine

Given IV or PO

DRUG

methotrexate

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (3)

98101

VA Puget Sound Health Care System, Seattle

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

99352

Pacific Northwest National Laboratory, Richland

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER